Detection and significance of minimal residual disease in colorectal cancer.
Detection and significance of minimal residual disease in colorectal cancer.
复制标题
结直肠癌微小残留病的检测及意义。
DOI：
10.14670/hh-14.561
复制
发表时间：
1999
影响因子：
2
通讯作者：
J. L. McCall
中科院分区：
文献类型：
--
作者：
A. Merrie;Kankatsu Yun;A. V. Rij;J. L. McCall
结直肠癌（CRC）是发达国家癌症死亡的最常见原因之一。虽然CRC的主要治疗是手术，但高达50%的患者在明显治愈性手术后因微小残留病（MRD）而复发。大多数发生明显转移到区域淋巴结以外的患者最终死于该疾病。目前，辅助化疗被用于提高常规组织病理学证实无其他扩散证据的区域淋巴结转移患者的生存率。在早期阶段识别转移性疾病的能力可能在将辅助治疗引导到当前方法未识别的复发高风险患者中具有相当大的益处。已经开发了几种检测MRD的技术，包括免疫组织化学和分子方法，但它们在临床实践中的作用尚未确定。本文的目的是审查这些技术及其潜在的临床应用中的管理CRC。
Colorectal cancer (CRC) is one of the most common causes of cancer death in the developed world. Although the primary treatment for CRC is surgical, disease relapse due to minimal residual disease (MRD) following apparently curative surgery occurs in up to fifty percent of patients. Most patients who develop overt metastases beyond the regional lymph nodes eventually die of the disease. At present adjuvant chemotherapy is used to improve survival in patients with metastases to regional lymph nodes demonstrated by routine histopathology with no other evidence of spread. The ability to identify metastatic disease at an earlier stage could be of considerable benefit in directing adjuvant therapy to patients at high risk of relapse who are not identified by current methods. Several techniques have been developed for the detection of MRD, including immunohistochemical and molecular methods, however their role in clinical practise is not yet established. The purpose of this paper is to review these techniques and their potential clinical use in the management of CRC.